close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

119.89 +1.79 (+1.52%)
Streaming Delayed Price Updated: 10:46 AM EDT, Aug 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
21 22 Next >
News headline image
CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Case Study in Affordable Growth Investing ↗
Discover Corcept Therapeutics (CORT), a debt-free pharma stock with strong growth forecasts, solid profitability, and a reasonable valuation for balanced investing. 
Via Chartmill
News headline image
1 Growth Stock with Explosive Upside and 2 We Brush Off
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT)
Looking back on branded pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Earnings Scheduled For November 4, 2025 ↗
 
Via Benzinga
News headline image
The 5 Most Interesting Analyst Questions From Corcept’s Q3 Earnings Call
Corcept Therapeutics’ third quarter results drew a negative market reaction as the company’s revenue missed Wall Street expectations, despite robust year-on-year growth. Management highlighted... 
Via StockStory
Topics Earnings
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Peering Into Corcept Therapeutics Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue... 
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue... 
Via StockStory
News headline image
Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Corcept Earnings: What To Look For From CORT
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be reporting results this Tuesday after market close. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Healthcare Stocks We Steer Clear Of
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, limiting growth. This... 
Via StockStory
Topics Stocks
News headline image
3 Cash-Producing Stocks with Open Questions
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
Beyond The Numbers: 6 Analysts Discuss Corcept Therapeutics Stock ↗
 
Via Benzinga
News headline image
Corcept Therapeutics Stock Slips Premarket Despite Strong Cancer Trial Data Showing 40% Drop In Disease Progression Risk ↗
Phase 3 ROSELLA trial showed relacorilant plus chemotherapy helped patients with platinum-resistant ovarian cancer live longer without disease worsening, including those who failed prior PARP inhibitor... 
Via Stocktwits
News headline image
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 That Underwhelm
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
News headline image
Corcept (CORT) Shares Skyrocket, What You Need To Know
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 7.7% in the afternoon session after it submitted a Marketing Authorization Application to the European Medicines Agency for its... 
Via StockStory
News headline image
Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 High-Flying Stocks We Approach with Caution
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
News headline image
3 Profitable Stocks That Concern Us
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Why Corcept (CORT) Shares Are Falling Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 12.3% in the morning session after reports of a significant stock sale by a top executive surfaced. The company's Chief Development... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Heavy Stock with Exciting Potential and 2 That Underwhelm
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
Via StockStory
News headline image
3 Low-Volatility Stocks We Think Twice About
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
Topics Government
News headline image
Why Corcept (CORT) Stock Is Trading Up Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) jumped 2.1% in the afternoon session after the company announced a specialty pharmacy partnership with Curant Health. Corcept has selected... 
Via StockStory
News headline image
Pharma ETFs In A Tariff Storm: How Investors Can Hedge Risk ↗
The U.S. pharmaceutical industry is at the center of a policy maelstrom. 
Via Benzinga
Topics ETFs
News headline image
4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals ↗
Four biotechnology stocks have surged into the top 10th percentile for momentum ranking, demonstrating remarkable week-on-week technical strength and strong price action. 
Via Benzinga
News headline image
1 Momentum Stock with Competitive Advantages and 2 We Find Risky
Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or... 
Via StockStory
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
21 22 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.